Archive | February, 2016

Crude Stabilizes then Biotech Turns Green: Stay Tuned But Cautious

Biotech Stocks Off  Lows Tracking Crude and Energy sector… 11.45 a EST Can healthcare stocks uncouple from energy and macro? Individual biotech stocks look very tradable with green catching up with red. But biotech stocks defy fundamental analysis with current random hourly volatility.  IBB up 0.12% off bottom of $254 XBI up 0.20% XLE up […]

Continue Reading 0

Biotech Stocks Lag Today’s Rally: S&P 500 Erases February Losses But Still Down 4.4% YTD…Update-1

2/23 After Close—Energy Rout Burns Biotech Stocks and NASDAQ The red screen dominated except few winners like ZIOPHARM Oncology (ZIOP) up 13.95% on a publication regarding gene editing. Another gene editing stock and recent IPO Editas Medicine (EDIT) was up 4.63% to $22.62. Large cap biopharma joined the sell-off and Fidelity Select Biotechnology Portfolio (FBIOX) […]

Continue Reading 0

Large Cap Biopharma Winners and Losers 2015-16: Which Stocks Can Beat the ETFs?… Part 2

Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our portfolio after the J.P.Morgan Healthcare Conference. Here are some parameters to watch that should help in stock picking: Stock […]

Continue Reading 0

Biotech Bear Market Update: Barely Bouncing Off the Bottom

Have we reached a tradeable bottom in the biotech bear market? Today’s tape showed good volume but gains faded late in session. NASDAQ up 0.35%         XLV up 0.88%-healthcare is the leading sector The biotech market bounced back early today in a broad rally then faded with the IBB up 0.625 % […]

Continue Reading 0

Three Biotech Stocks To Buy Now: ABBV,BLUE,GILD…Update-2

2/5/16 …11:20 AM Biotechs Can’t Hold Gains …Drop Back Near 52 Week Lows Hit Wednesday IBB $261  XBI $48 Update-2 At Close 2/4/16…Nice Rally But Off Earlier Highs-Very Stock Specific A nice snap-back rally with a lot of green screen across the board. A tradeable rally but we need follow-through next week. Your favorite stock […]

Continue Reading 0

Large Cap Biopharmaceuticals Winners and Losers 2015-16: Which Stocks Can Outperform the ETFs in 2016?… Part 1

Where is the Growth Potential in Large Cap Biopharmaceutical Companies? Caution: Risk Aversion Remains High Investing in biotech stocks ain’t getting easier. The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug pricing and even the spectre of a FED rate rise, with potentially less available equity funding, […]

Continue Reading 0

Rayno Dx and Tools: Abbott (ABT) Buys Alere (ALR) For $5.8B Expanding Point-of-Care Diagnostics Platforms

Abbott Laboratories Acquires Alere (ALR) -Stock Soars 45% At Market Opening Alere Product Line Offers Synergies and Boosts Global Diagnostics Presence 2015 Revenues of Alere Are Estimated in $2.5B Range So Deal is About 2.3X Sales Alere (ALR) has a broad-based product line in rapid point-of-care diagnostics with tests for infectious disease such as influenza […]

Continue Reading 0